Lensar Inc Stock Price, News & Analysis

LENSAR, Inc. (NASDAQ: LNSR) has announced that CEO Nick Curtis will present at two upcoming investor conferences. The first, the Piper Sandler 33rd Annual Virtual Healthcare Conference, will feature an on-demand presentation available starting November 22 at 10:00 a.m. ET. The second event, BTIG Ophthalmology Day, will include a fireside chat on November 30 at 8:00 a.m. ET. The Piper Sandler presentation can be accessed on the Company’s website, where it will be available for one month after being posted.

LENSAR, Inc. (NASDAQ: LNSR) announced two poster presentations accepted for the American Academy of Ophthalmology (AAO) Annual Meeting, scheduled for November 12-15, 2021. The presentations highlight the use of LENSAR's femtosecond laser technology in improving astigmatic outcomes during cataract surgery. The topics are:

• Femtosecond Laser Image Guided Corneal Arcuate Incisions for Managing Mild Keratometric Astigmatism in Cataract Surgery
• Toric IOL alignment with femtosecond laser capsular marks confirmed by intraoperative aberrometry

LENSAR (Nasdaq: LNSR) reported a 16% revenue increase for Q3 2021, totaling $8.3 million, driven by a 23% rise in procedure volumes compared to Q3 2020. Cash and cash equivalents stood at $32.3 million after $2.2 million in cash utilization for the quarter. The company anticipates a 510(k) filing for its ALLY™ Adaptive Cataract Treatment System in Q1 2022. However, the net loss for the quarter widened to $6.2 million, or ($0.65) per share. R&D expenses surged 59% to $3.2 million, primarily for the development of the ALLY system.

LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2021 financial results on November 8, 2021, before market open. A conference call and webcast will follow at 8:30am ET on the same day to discuss these results and corporate highlights. LENSAR specializes in advanced femtosecond laser technologies for cataract treatment, aiming to improve visual outcomes for patients through its proprietary laser system.

LENSAR, Inc. (Nasdaq: LNSR) has announced that CEO Nick Curtis will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with the presentation available on-demand from 7:00 a.m. Eastern Time. The webcast can be accessed through the company's website and will remain available for one month following the event. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, aiming to improve surgical outcomes through innovative technology.

LENSAR, a global medical technology leader in femtosecond laser surgical solutions for cataracts, announced CEO Nick Curtis will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET and can be accessed through the Company's website. LENSAR specializes in advanced laser systems designed to improve visual outcomes and efficiency in cataract surgery.

LENSAR, Inc. (Nasdaq: LNSR) reported significant financial growth for Q2 2021, achieving a 57% increase in total revenue to $7.9 million compared to Q2 2020, driven by a 70% rise in procedure volume. The company’s recurring revenue rose to 90%, up from 78% the previous year. Despite this growth, LENSAR recorded a net loss of $4.4 million, slightly improved from a loss of $4.5 million in Q2 2020. R&D expenses surged by 110% to $3 million, reflecting continued development of the ALLY system, expected to launch in 2022. The company maintained a cash position of $34.6 million.

LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2021 financial results on August 5, 2021, before market open. A conference call and webcast will follow at 8:30 am ET on the same day to discuss the results and recent corporate highlights. LENSAR specializes in advanced femtosecond laser surgical solutions for cataract treatment, utilizing proprietary technologies aimed at enhancing surgical outcomes and efficiency.

LENSAR, Inc. (NASDAQ: LNSR) announced the acceptance of 12 abstracts showcasing its advanced femtosecond laser technology at the 2021 ASCRS Annual Meeting from July 23-27 in Las Vegas. The company will also demonstrate its next-gen ALLY™ Adaptive Cataract Treatment System, with a 510(k) application expected in Q1 2022 and a commercial launch planned for later that year. CEO Nick Curtis emphasized the significance of these presentations in validating LENSAR's innovations and improving patient outcomes in cataract surgeries.